$STEX

Streamex Corp. Announces First Independent Reserve Attestation by EisnerAmper for GLDY

Streamex Corp. (NASDAQ: STEX) said EisnerAmper completed its first independent reserve attestation for GLDY, a gold-backed yield-bearing token. The exam covered gold held and leased as of March 31, 2026, and found 3,064.674268 GLDY tokens backed by 3,064.915910 fine troy ounces (≥100% coverage) with an unmodified opinion. Monthly attestations are planned.

Original reporting
Published Jul 1, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 12:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Streamex Corp. Announces First Independent Reserve Attestation by EisnerAmper for GLDY — source image
Decision brief

The 30-second read

$STEXBullishMed
01

Why it matters

EisnerAmper’s examination (AICPA/SSAE) covers gold held in approved vaults plus gold deployed under a leasing program with Monetary Metals, with coverage reported at ≥100% and an unmodified opinion. This is intended to strengthen institutional trust and ongoing transparency.

02

Market read

The article provides a concrete, first-time third-party reserve attestation result and a monthly cadence plan, which can shift perceived backing credibility for GLDY and sentiment toward STEX.

03

What to watch

The release doesn’t quantify expected changes in GLDY issuance, AUM, fees, or yield sustainability; traders may need follow-through data on token growth and subsequent monthly attestations to validate the impact.

Relevance 6/10Novelty 7/10Timing: today’s press release on first reserve attestation (as of March 31, 2026)

Background

Streamex’s GLDY is a gold-backed, yield-bearing tokenized security; the company is introducing recurring third-party reserve attestations.

Company-level read

Ticker impact

$STEXBullishMedium confidence
Context

Streamex (NASDAQ: STEX) announces EisnerAmper’s first independent reserve attestation for GLDY, starting monthly third-party checks.

Expected impact

Near-term: modest positive bias if investors view the attestation as reducing redemption/backing risk; longer-term depends on continued monthly attestations and any changes in coverage.

Evidence & confidence

The article discloses a concrete, time-stamped attestation result (≥100% coverage, unmodified opinion) and a forward cadence (monthly). However, it provides no direct financial impact, guidance, or token flow data, limiting magnitude.

Market effects

Supports the broader tokenized-RWA market’s push toward recurring third-party reserve assurance, potentially raising expectations for similar issuers’ transparency.

Limited direct regional impact; primarily affects US-listed issuer sentiment and investor perception of tokenized commodity products.

Could modestly influence global investor comfort with gold-backed tokenization models if monthly attestations become a de facto standard.

Counterpoint

A single attestation (even unmodified) may not materially change redemption risk if investors focus on operational/lease counterparty risk and future reserve coverage trends.

Key entities

  • Streamex Corp.

    NASDAQ-listed issuer of GLDY tokenized gold security (STEX).

  • GLDY

    Gold-backed, yield-bearing tokenized security whose reserves are being attested.

  • EisnerAmper LLP

    Independent registered public accounting firm conducting the reserve examination.

  • Monetary Metals

    Counterparty in the gold leasing program referenced in the reserve composition.

  • Chainlink Proof of Reserves Oracle

    Referenced as a source for real-time GLDY reserve/NAV data.

Related articles

$STEXLow

Streamex Corp. (STEX): Results of Operations and Financial Condition

Streamex Corp. (STEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Streamex Corp. Reports Second Quarter 2026 Financial Results WINTER PARK, Fla., August 17, 2026 (GLOBE NEWSWIRE) — Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a technology company building the future of the commodity markets through tokenization, tod

$STEXMed

Streamex Corp. Announces 24/7, 365 Instant Liquidity for GLDY Through Collaboration with Wintermute

Streamex Corp. (NASDAQ: STEX) said it expanded 24/7, T+0 liquidity for GLDY, its gold-backed yield-bearing token, by adding Wintermute as a continuous liquidity provider. Streamex seeded 1,069 GLDY and $5 million USDC, bringing secondary liquidity to about $12 million. Purchases and redemptions now settle instantly via the Streamex interface, with a 1,000 GLDY or $4.5 million per 48-hour limit per order.

$STEXMed

Streamex is making digital gold accessible

Streamex Corp. (NASDAQ: STEX) said its gold-backed tokenized security $GLDY can now be bought through ordinary brokerage accounts via a collaboration with Siebert Financial and tZERO. $GLDY pays yield up to ~3.5% annually, distributed monthly in additional gold, and is currently available to verified accredited investors.

$STEXMed

Streamex Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and Design

Streamex Corp. (NASDAQ: STEX) said it appointed Kori Handy as Vice President of Product and Design. The company said Handy has 18 years of fintech/SaaS product experience, including scaling platforms to $2B+ in assets under management and 200M+ users. Streamex said he previously led redesigns at Groundfloor, driving a 32% activation increase and 27% higher cash deposits. He will oversee the GLDY user experience and future tokenized real-asset product launches.

$CYTKMedAI 8/10

Could Aficamten Give Cytokinetics the First Approved nHCM Treatment?

Cytokinetics (NASDAQ:CYTK) reported late-stage trial results for aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM), meeting primary goals of improving symptoms and quality of life. The study showed 53% of patients on aficamten improved in key areas vs. 13% on placebo, but lacked significant structural or cardiovascular benefits. The company plans a US marketing application in Q4 2026. Analysts forecast peak sales of over $5 billion for Myqorzo, but investors expressed concerns over

$CCJMed

Jefferies Sees Cameco (CCJ) and BWXT as Winners in the Nuclear Boom

Jefferies initiated coverage of Cameco (CCJ) and BWXT (BWXT) with 'Buy' ratings, setting price targets of $138 and $181 respectively, citing strong long-term prospects in nuclear energy. CCJ, a major uranium producer, and BWXT, a nuclear reactor provider, are positioned to benefit from global and U.S. initiatives to expand nuclear capacity. Both companies face risks, including uranium price volatility for CCJ and execution challenges for BWXT.